- Home
- SUPN vs JBLU Comparison
SUPN vs JBLU Comparison
Compare SUPN & JBLU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SUPN | JBLU |
|---|---|---|
| Founded | 2005 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Air Freight/Delivery Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 1.5B |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | SUPN | JBLU |
|---|---|---|
| Price | $51.66 | $4.71 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 5 | 9 |
| Target Price | ★ $61.60 | $4.76 |
| AVG Volume (30 Days) | 636.6K | ★ 16.9M |
| Earning Date | 11-04-2025 | 01-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $681,539,000.00 | ★ $9,095,000,000.00 |
| Revenue This Year | $8.32 | N/A |
| Revenue Next Year | $23.36 | $8.18 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.54 | N/A |
| 52 Week Low | $29.16 | $3.34 |
| 52 Week High | $57.65 | $8.31 |
Technical Indicators
Market Signals| Indicator | SUPN | JBLU |
|---|---|---|
| Relative Strength Index (RSI) | 67.82 | 49.42 |
| Support Level | $51.01 | $4.72 |
| Resistance Level | $52.30 | $4.99 |
| Average True Range (ATR) | 1.49 | 0.21 |
| MACD | 0.65 | -0.03 |
| Stochastic Oscillator | 89.77 | 12.26 |
Price Performance
Historical ComparisonAbout SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
About JBLU JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It served approximately 100 destinations in the United States, the Caribbean and Latin America, Canada, and England. The company currently operates Airbus A321, Airbus A320, Airbus A321neo, and Embraer E190 aircraft types. The company has one operating segment, Air Transportation Services, which provides services in the United States, the Caribbean, Latin America, Canada, and Europe. The majority of revenue is generated from the Domestic & Canada segment.